Online citations, reference lists, and bibliographies.
← Back to Search

Asialoglycoprotein Receptor Mediated Hepatocyte Targeting - Strategies And Applications.

A. D’souza, P. Devarajan
Published 2015 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Hepatocyte resident afflictions continue to affect the human population unabated. The asialoglycoprotein receptor (ASGPR) is primarily expressed on hepatocytes and minimally on extra-hepatic cells. This makes it specifically attractive for receptor-mediated drug delivery with minimum concerns of toxicity. ASGPR facilitates internalization by clathrin-mediated endocytosis and exhibits high affinity for carbohydrates specifically galactose, N-acetylgalactosamine and glucose. Isomeric forms of sugar, galactose density and branching, spatial geometry and galactose linkages are key factors influencing ligand-receptor binding. Popular ligands for ASGPR mediated targeting are carbohydrate polymers, arabinogalactan and pullulan. Other ligands include galactose-bearing glycoproteins, glycopeptides and galactose modified polymers and lipids. Drug-ligand conjugates provide a viable strategy; nevertheless ligand-anchored nanocarriers provide an attractive option for ASGPR targeted delivery and are widely explored. The present review details various ligands and nanocarriers exploited for ASGPR mediated delivery of drugs to hepatocytes. Nanocarrier properties affecting ASGPR mediated uptake are discussed at length. The review also highlights the clinical relevance of ASGPR mediated targeting and applications in diagnostics. ASGPR mediated hepatocyte targeting provides great promise for improved therapy of hepatic afflictions.
This paper references
10.1016/S0378-5173(99)00206-9
Enhanced hepatocyte uptake and liver targeting of methotrexate using galactosylated albumin as a carrier.
J. H. Han (1999)
10.2741/A806
Targeting hepatocytes for drug and gene delivery: emerging novel approaches and applications.
J. Wu (2002)
10.1248/BPB.28.195
Development of cell-specific targeting systems for drugs and genes.
M. Nishikawa (2005)
10.1016/S0168-3659(01)00411-4
Efficiency of liposomes surface-modified with soybean-derived sterylglucoside as a liver targeting carrier in HepG2 cells.
Y. Maitani (2001)
Larch arabinogalactan: clinical relevance of a novel immune-enhancing polysaccharide.
G. S. Kelly (1999)
10.1038/sj.gt.3301840
Increased receptor-mediated gene delivery to the liver by protamine-enhanced-asialofetuin-lipoplexes
M. A. Arangoa (2003)
10.1007/s00259-013-2397-8
Development of 68Ga-labelled DTPA galactosyl human serum albumin for liver function imaging
R. Haubner (2013)
10.1021/bm401098w
Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
Yinan Zhong (2013)
10.1016/0014-4827(86)90602-6
Endocytosis via galactose receptors in vivo. Ligand size directs uptake by hepatocytes and/or liver macrophages.
J. Schlepper-Schäfer (1986)
Preoperative assessment of residual hepatic functional reserve using 99mTc-DTPA-galactosyl-human serum albumin dynamic SPECT.
E. H. Hwang (1999)
10.1016/S0169-409X(01)00109-0
Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting.
P. C. Rensen (2001)
10.1016/j.jconrel.2012.05.052
Challenges in design and characterization of ligand-targeted drug delivery systems.
S. Muro (2012)
10.1016/0304-4165(87)90213-3
Drug delivery using vesicles targeted to the hepatic asialoglycoprotein receptor.
P. Dragsten (1987)
10.1016/j.ijpharm.2010.09.012
Polyethylene sebacate-doxorubicin nanoparticles for hepatic targeting.
Swati A. Guhagarkar (2010)
10.1016/S0006-2952(97)00223-2
Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis.
G. Di Stefano (1997)
10.1016/J.IJPHARM.2005.05.020
Uptake characteristics of galactosylated emulsion by HepG2 hepatoma cells.
Chittima Managit (2005)
10.1023/B:PHAM.0000029280.39882.ff
Biodistribution Characteristics of Galactosylated Emulsions and Incorporated Probucol for Hepatocyte-Selective Targeting of Lipophilic Drugs in Mice
Emi Ishida (2004)
10.1080/15257770.2011.649331
Novel Neo Glycolipid: Formulation into Pegylated Cationic Liposomes and Targeting of DNA Lipoplexes to the Hepatocyte-Derived Cell Line HepG2
Nicolisha Narainpersad (2012)
10.1158/0008-5472.CAN-11-2890
Nanocarriers enhance Doxorubicin uptake in drug-resistant ovarian cancer cells.
H. Arora (2012)
10.1158/1078-0432.CCR-10-0498
Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy
W. Xu (2011)
10.1016/J.JCONREL.2007.01.005
Expression profile of plasmid DNA by spermine derivatives of pullulan with different extents of spermine introduced.
Jun-ichiro Jo (2007)
10.1016/S0925-4439(98)00044-1
Biochemical and molecular aspects of genetic disorders of bilirubin metabolism.
T. Iyanagi (1998)
クリノアタカマイトCu2(OH)3ClとテノライトCuOナノ粒子のpH制御選択合成
Engelbrekt Christian (2014)
10.1016/j.biomaterials.2011.03.069
The performance of gadolinium diethylene triamine pentaacetate-pullulan hepatocyte-specific T1 contrast agent for MRI.
Hyeona Yim (2011)
10.1128/AEM.70.6.3407-3416.2004
Cloning, Sequencing, and Characterization of a Heat- and Alkali-Stable Type I Pullulanase from Anaerobranca gottschalkii
C. Bertoldo (2004)
10.1002/cbic.200400334
Smart Polyion Complex Micelles for Targeted Intracellular Delivery of PEGylated Antisense Oligonucleotides Containing Acid‐Labile Linkages
Motoi Oishi (2005)
Subcellular membrane topology and turnover of a rat hepatic binding protein specific for asialoglycoproteins.
T. Tanabe (1979)
10.1016/j.jconrel.2010.01.036
Endocytosis of nanomedicines.
G. Sahay (2010)
10.1016/0008-6215(87)85003-6
Synthesis of D-galactosamine derivatives and binding studies using isolated rat hepatocytes.
T. C. Wong (1987)
10.1016/0005-2736(83)90072-X
Targeting of lactosylceramide-containing liposomes to hepatocytes in vivo.
H. H. Spanjer (1983)
10.1021/bm4002409
Galactosylated micelles for a ribavirin prodrug targeting to hepatocytes.
E. Craparo (2013)
10.1111/j.1742-4658.2012.08643.x
NMR study of ligand release from asialoglycoprotein receptor under solution conditions in early endosomes
T. Onizuka (2012)
10.1021/bm201270m
Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin.
Cunxian Duan (2011)
10.1007/BF00389966
Inhibition of liver metastasis in mice by blocking hepatocyte lectins with arabinogalactan infusions and d-galactose
J. Beuth (1987)
10.1016/j.colsurfb.2014.07.010
PEGylated galactosylated cationic liposomes for hepatocytic gene delivery.
K. Naicker (2014)
10.1248/BPB.28.560
Uptake of pullulan in cultured rat liver parenchymal cells.
T. Tanaka (2005)
10.1152/PHYSREV.1995.75.3.591
The asialoglycoprotein receptor: relationships between structure, function, and expression.
R. Stockert (1995)
10.3109/1061186X.2013.769105
Design and evaluation of polyamidoamine dendrimer conjugate with PEG, α-cyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo
Y. Hayashi (2013)
10.1016/j.jconrel.2014.06.001
Glycosylation-mediated targeting of carriers.
S. Kawakami (2014)
10.1002/JBM.A.31328
Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo.
L. Dong (2008)
10.1016/S0168-8278(94)80243-2
Specific targeting of the antiviral drug 5-iodo 2'-deoxyuridine to the parenchymal liver cell using lactosylated poly-L-lysine.
E. A. Biessen (1994)
10.1016/S0142-9612(03)00633-1
Preparation of lactose-silk fibroin conjugates and their application as a scaffold for hepatocyte attachment.
Yohko Gotoh (2004)
10.1016/J.JCONREL.2005.12.023
Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting.
T. Terada (2006)
10.1021/BC00028A004
Preparation of asialoorosomucoid-polylysine conjugates.
T. Mckee (1994)
10.1021/ja1021766
In silico prediction of the 3D structure of trimeric asialoglycoprotein receptor bound to triantennary oligosaccharide.
Sai Kumar Ramadugu (2010)
10.1016/j.bmc.2011.03.027
New and more efficient multivalent glyco-ligands for asialoglycoprotein receptor of mammalian hepatocytes.
R. Lee (2011)
10.1016/S0168-3659(01)00390-X
Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene.
C. Cho (2001)
10.1016/J.BIOMATERIALS.2007.04.004
Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate.
Payal Agrawal (2007)
10.1016/j.biomaterials.2010.11.068
N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers.
S. Medina (2011)
10.1002/1097-0290(20001220)70:6<593::AID-BIT1>3.0.CO;2-N
Receptor‐mediated targeting of gene delivery vectors: Insights from molecular mechanisms for improved vehicle design
Csanad M. Varga (2000)
10.1016/S0142-9612(01)00399-4
Preparation of alginate/galactosylated chitosan scaffold for hepatocyte attachment.
Taek Woong Chung (2002)
10.1007/s12272-009-1714-z
Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-κB-inducing kinase-specific siRNA using liver-targeting liposomes
Hyun-ah Cho (2009)
10.1016/j.apradiso.2012.12.009
The preparation of 99mTc-DTPA-LSA and its instant lyophilized kit for hepatic receptor imaging.
W. Yang (2013)
10.1083/JCB.98.2.732
Recycling of the asialoglycoprotein receptor and the effect of lysosomotropic amines in hepatoma cells
A. Schwartz (1984)
10.1042/BJ2990285
Characterization of the interaction of galactose-exposing particles with rat Kupffer cells.
J. Kuiper (1994)
10.1016/J.JCONREL.2006.11.006
Mechanisms of co-modified liver-targeting liposomes as gene delivery carriers based on cellular uptake and antigens inhibition effect.
Y. Zhang (2007)
10.1016/j.jconrel.2008.07.029
Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting.
Hu-Lin Jiang (2008)
10.1371/journal.pone.0046096
Inhibition of Hepatitis B Virus and Induction of Hepatoma Cell Apoptosis by ASGPR-Directed Delivery of shRNAs
J. Ma (2012)
10.1016/j.jconrel.2014.09.025
Development of lipid nanoparticle formulations of siRNA for hepatocyte gene silencing following subcutaneous administration.
Sam Chen (2014)
10.1023/A:1016053128569
Development and Pharmacokinetics of Galactosylated Poly-L-Glutamic Acid as a Biodegradable Carrier for Liver-Specific Drug Delivery
Hideki Hirabayashi (2004)
10.1046/j.1365-2893.1997.00067.x
Liver targeting of antiviral nucleoside analogues through the asialoglycoprotein receptor
L. Fiume (1997)
10.1016/J.JCONREL.2005.03.011
Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocyte-targeting gene carrier.
S. E. Cook (2005)
10.1016/S0378-5173(00)00405-1
Pharmacokinetics and biodisposition of fluorescein-labeled arabinogalactan in rats.
Y. Kaneo (2000)
10.1021/JM00009A014
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor.
E. A. Biessen (1995)
10.1016/S0168-3659(01)00555-7
A new synthesis of galactose-poly(ethylene glycol)-polyethylenimine for gene delivery to hepatocytes.
K. Sagara (2002)
10.3109/10717540903580176
Galactosylated solid lipid nanoparticles with cucurbitacin B improves the liver targetability
W. Wang (2010)
10.1016/S0076-6879(10)79013-3
The Ashwell-Morell receptor.
Prabhjit K. Grewal (2010)
10.1016/J.IJPHARM.2005.01.026
Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting.
D. Bhadra (2005)
10.1016/0304-4165(78)90196-4
Elimination of asialofetuin and asialoorosomucoid by the intact rat. Quantitative aspects of the hepatic clearance mechanism.
E. Regoeczi (1978)
10.1016/j.biomaterials.2013.10.029
In vivo hepatocyte MR imaging using lactose functionalized magnetoliposomes.
A. Ketkar-Atre (2014)
Human hepatic lectin. Physiochemical properties and specificity.
J. Baenziger (1980)
10.1016/S0142-9612(03)00108-X
Galactosylated chitosan as a synthetic extracellular matrix for hepatocytes attachment.
I. Park (2003)
10.1002/DDR.20069
Targeted nanoparticles for detecting and treating cancer
C. J. Sunderland (2006)
10.1021/JM981078H
Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor.
L. A. Sliedregt (1999)
10.1002/bjs.7025
Preoperative estimation of remnant hepatic function using fusion images obtained by 99mTc‐labelled galactosyl‐human serum albumin liver scintigraphy and computed tomography
Y. Yumoto (2010)
10.1101/GLYCOBIOLOGY.3E.031
R-type Lectins
R. Cummings (2009)
10.1007/BF02439544
Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicentre study
S. K. Ha-Kawa (2006)
10.1016/j.biomaterials.2014.01.036
A biocleavable pullulan-based vector via ATRP for liver cell-targeting gene delivery.
Xinchao Yang (2014)
10.3109/08982100902838682
Formulation and evaluation of ATP-containing liposomes including lactosylated ASGPr ligand
K. Tep (2009)
10.2147/IJN.S33965
Lactosylated liposomes for targeted delivery of doxorubicin to hepatocellular carcinoma
Xiaoju Zhou (2012)
10.1016/j.jcis.2013.04.025
Surface grafted glycopolymer brushes to enhance selective adhesion of HepG2 cells.
Sergey Chernyy (2013)
10.1046/J.1432-1327.2000.01747.X
α3‐Galactosylated glycoproteins can bind to the hepaticasialoglycoprotein receptor
D. Joziasse (2000)
10.1016/S0168-3659(02)00458-3
Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency.
K. Kunath (2003)
10.1016/S0168-3659(03)00360-2
Targeted gene delivery into HepG2 cells using complexes containing DNA, cationized asialoorosomucoid and activated cationic liposomes.
M. Singh (2003)
10.1074/JBC.271.12.6679
Structural Basis of Galactose Recognition by C-type Animal Lectins (*)
A. Kolatkar (1996)
Binding and endocytosis of cluster glycosides by rabbit hepatocytes. Evidence for a short-circuit pathway that does not lead to degradation.
D. Connolly (1982)
Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat heptocytes.
K. Rice (1990)
10.1046/j.1365-2893.2003.00487.x
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
Daniel Lavanchy (2004)
10.1002/HEP.510250407
Hepatic lobar differences in progression of chronic liver disease: Correlation of asialoglycoprotein scintigraphy and hepatic functional reserve
S. Matsuzaki (1997)
10.3390/ph5010061
Potential Use of Polyamidoamine Dendrimer Conjugates with Cyclodextrins as Novel Carriers for siRNA
Hidetoshi Arima (2011)
10.1089/CDD.1987.4.145
Conjugates of ara-AMP with lactosaminated albumin: a study on their immunogenicity in mouse and rat.
L. Fiume (1987)
10.1016/j.jconrel.2012.12.017
N-acetylgalactosamine functionalized mixed micellar nanoparticles for targeted delivery of siRNA to liver.
H. Wang (2013)
10.1038/sj.cgt.7700985
Inhibition of hepatocarcinoma by systemic delivery of Apoptin gene via the hepatic asialoglycoprotein receptor
D-J Peng (2007)
10.1016/j.biomaterials.2008.12.074
Cationic glycolipids with cyclic and open galactose head groups for the selective targeting of genes to mouse liver.
Rajesh Mukthavaram (2009)
10.1002/1520-6017(200102)90:2<105::AID-JPS1>3.0.CO;2-1
Novel galactosylated liposomes for hepatocyte-selective targeting of lipophilic drugs.
S. Kawakami (2001)
10.1007/BF03219061
Immobilization of lactobionic acid on polyurethane films and their interaction with hepatocytes
Wan Meng (2005)
10.1016/S0168-3659(97)00263-0
Targeted delivery of plasmid DNA complexed with galactosylated poly(L-lysine).
M. Hashida (1998)
10.1016/J.BIOMATERIALS.2005.06.008
Galactose-carrying polymers as extracellular matrices for liver tissue engineering.
Chong-su Cho (2006)
10.1208/s12248-013-9474-6
Comparative In Silico–In Vivo Evaluation of ASGP-R Ligands for Hepatic Targeting of Curcumin Gantrez Nanoparticles
A. D’souza (2013)
10.1016/j.jconrel.2013.03.020
Lactosylated gramicidin-based lipid nanoparticles (Lac-GLN) for targeted delivery of anti-miR-155 to hepatocellular carcinoma.
Mengzi Zhang (2013)
10.1007/s00534-010-0264-6
Preoperative estimation of asialoglycoprotein receptor expression in the remnant liver from CT/99mTc-GSA SPECT fusion images correlates well with postoperative liver function parameters
Y. Iimuro (2010)
10.1080/10611860400024714
Targeted gene delivery to hepatoma cells using galactosylated liposome-polycation-DNA complexes (LPD)
Xun Sun (2005)
10.1016/j.talanta.2006.05.064
Identification of live liver cancer cells in a mixed cell system using galactose-conjugated fluorescent nanoparticles.
Jiaofeng Peng (2007)
10.1002/JPS.20443
Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes.
Chittima Managit (2005)
10.1208/s12249-010-9422-z
Development and In Vitro Characterization of Galactosylated Low Molecular Weight Chitosan Nanoparticles Bearing Doxorubicin
N. Jain (2010)
10.1002/HEP.510280227
Circulating cellular fibronectin may be a natural ligand for the hepatic asialoglycoprotein receptor: Possible pathway for fibronectin deposition and turnover in the rat liver
R. Rotundo (1998)
10.1016/J.BIOMATERIALS.2003.10.063
Galactosylated chitosan/DNA nanoparticles prepared using water-soluble chitosan as a gene carrier.
T. Kim (2004)
10.1016/J.JCONREL.2004.01.003
Lactose-conjugated polyion complex micelles incorporating plasmid DNA as a targetable gene vector system: their preparation and gene transfecting efficiency against cultured HepG2 cells.
Daisuke Wakebayashi (2004)
10.1111/j.1525-1594.2009.00746.x
Coatings of low-density lipoprotein and synthetic glycoconjugates as substrata for hepatocytes.
H. Yura (2009)
10.1166/JBN.2007.034
Hepatocyte-Selective Gene Transfer by Galactosylated Protein/Linear Polyethyleneimine/Plasmid DNA Complexes in Mice
Miyuki Hohokabe (2007)
10.1016/j.cca.2009.06.035
Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA--revival of a disease-activity marker in autoimmune hepatitis.
G. Hausdorf (2009)
10.1016/J.IJPHARM.2005.12.014
Delivery of different length poly(L-lysine)-conjugated ODN to HepG2 cells using N-stearyllactobionamide-modified liposomes and their enhanced cellular biological effects.
S. Wang (2006)
10.1016/S0168-3659(02)00197-9
Liver targeting of human interferon-β with pullulan based on metal coordination
Y. Suginoshita (2002)
10.1016/S0168-3659(97)00157-0
Pharmacokinetic analysis of hepatic uptake of galactosylated bovine serum albumin in a perfused rat liver.
K. Ogawara (1998)
In vitro cytotoxicity studies of hydrogel pullulan nanoparticles prepared by AOT/N-hexane micellar system.
Mona Gupta (2004)
10.1248/BPB.20.881
Formulation of liposomes with a soybean-derived sterylglucoside mixture and cholesterol for liver targeting.
K. Shimizu (1997)
10.1016/j.biomaterials.2009.12.022
Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery.
Fabian Suriano (2010)
10.1007/s12645-011-0012-x
Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line
Swati A. Guhagarkar (2011)
10.1163/092050611X558297
Study on Galactose–Poly(Ethylene Glycol)–Poly(L-Lysine) as Novel Gene Vector for Targeting Hepatocytes In Vitro
Hai-mei Hu (2012)
10.1088/0957-4484/24/47/475103
Galactosylated manganese ferrite nanoparticles for targeted MR imaging of asialoglycoprotein receptor.
Seung-hyun Yang (2013)
10.1007/s12149-011-0520-0
Usefulness of Tc-99m-GSA scintigraphy for liver surgery
M. Kaibori (2011)
10.1016/S0168-3659(00)00298-4
Galactosylated chitosan-graft-dextran as hepatocyte-targeting DNA carrier.
I. Park (2000)
10.1002/jbm.a.34680
High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting.
H. Li (2014)
10.1016/j.biomaterials.2010.11.005
The labeling of cationic iron oxide nanoparticle-resistant hepatocellular carcinoma cells using targeted magnetoliposomes.
S. Soenen (2011)
10.1016/J.JCONREL.2006.12.019
Novel histidine-conjugated galactosylated cationic liposomes for efficient hepatocyte-selective gene transfer in human hepatoma HepG2 cells.
Kosuke Shigeta (2007)
10.1248/BPB.34.1338
Galactose-modified cationic liposomes as a liver-targeting delivery system for small interfering RNA.
S. Sonoke (2011)
10.1016/S0168-8278(97)80038-4
Hepatotropic conjugate of adenine arabinoside monophosphate with lactosaminated poly-L-lysine. Synthesis of the carrier and pharmacological properties of the conjugate.
L. Fiume (1997)
10.1007/S10847-010-9842-0
In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/α-cyclodextrin conjugates into hepatocytes
K. Motoyama (2011)
10.1016/J.CARBPOL.2006.06.017
Synthesis of multifunctional chitosan with galactose as a targeting ligand for glycoprotein receptor
W. Lin (2007)
10.1016/J.EJPB.2005.07.004
Synthesis of a novel galactosylated lipid and its application to the hepatocyte-selective targeting of liposomal doxorubicin.
Shao-Ning Wang (2006)
10.1007/BF02480029
Separation of mouse hepatocytes of distinct biological phenotypes based on their asialoglycoprotein receptor-mediated adhesion to an artificial ligand
H. Ise (2006)
10.1016/j.bmc.2009.08.049
Design, synthesis and evaluation of monovalent ligands for the asialoglycoprotein receptor (ASGP-R).
Daniela Stokmaier (2009)
10.1002/hep.23060
Long‐term reduction of jaundice in Gunn rats by nonviral liver‐targeted delivery of Sleeping Beauty transposon
X. Wang (2009)
10.1016/J.BIOMATERIALS.2006.09.014
Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes.
K. M. Kamruzzaman Selim (2007)
Characterization of the asialoglycoprotein receptor on isolated rat hepatocytes.
P. Weigel (1980)
10.1016/J.POLYMER.2008.09.006
Preparation, characterization and controlled release of liver-targeting nanoparticles from the amphiphilic random copolymer
X. Li (2008)
Receptor-mediated in vitro gene transformation by a soluble DNA carrier system.
G. Wu (1987)
10.1016/j.phrs.2011.06.015
A galactosamine-mediated drug delivery carrier for targeted liver cancer therapy.
Zheyu Shen (2011)
10.1016/j.bmc.2013.06.028
Liver-targeting of primaquine-(poly-γ-glutamic acid) and its degradation in rat hepatocytes.
N. Tomiya (2013)
10.1016/J.DLD.2005.11.006
Doxorubicin coupled to lactosaminated albumin: enhanced drug levels in rat hepatocarcinomas.
G. Di Stefano (2006)
10.1016/j.jconrel.2012.12.006
Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions.
J. Ding (2013)
10.1039/C4PY00024B
Galactosylated biodegradable poly(ε-caprolactone-co-phosphoester) random copolymer nanoparticles for potent hepatoma-targeting delivery of doxorubicin
Tao Yunfeng (2014)
10.1007/S00534-005-0986-Z
Hepatocyte transplantation for total liver repopulation.
T. Mizuguchi (2005)
10.1016/j.jconrel.2012.02.011
Drug targeting to the diseased liver.
K. Poelstra (2012)
10.1016/J.JCONREL.2005.03.021
Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells.
Hsiang-Fa Liang (2005)
10.1007/s13346-014-0200-4
Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand
V. Joshi (2014)
Kinetics of internalization and recycling of the asialoglycoprotein receptor in a hepatoma cell line.
A. Schwartz (1982)
10.1021/bm401749t
Glyco-nanoparticles with sheddable saccharide shells: a unique and potent platform for hepatoma-targeting delivery of anticancer drugs.
Wei Chen (2014)
10.1016/S0168-3659(98)00124-2
Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.
P. Julyan (1999)
10.1016/J.IJPHARM.2006.06.034
Cytotoxic effect induced by retinoic acid loaded into galactosyl-sphingosine containing liposomes on human hepatoma cell lines.
C. Díaz (2006)
10.1002/JBM.A.31062
Cationized pullulan 3D matrices as new materials for gene transfer.
A. San Juan (2007)
10.1016/S0005-2736(97)00036-9
Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s.
K. Shimada (1997)
10.1042/BJ3020283
Cholesterol derivative of a new triantennary cluster galactoside directs low- and high-density lipoproteins to the parenchymal liver cell.
E. A. Biessen (1994)
10.1021/mp400412c
In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Cui-Yun Yu (2014)
10.2147/IJN.S30034
Uptake and transport of a novel anticancer drug-delivery system: lactosyl-norcantharidin-associated N-trimethyl chitosan nanoparticles across intestinal Caco-2 cell monolayers
M. Guan (2012)
10.1016/S0168-3659(02)00201-8
Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination.
H. Hosseinkhani (2002)
10.1016/S0378-5173(03)00383-1
Targeted and sustained drug delivery using PEGylated galactosylated liposomes.
Chittima Managit (2003)
10.1016/0378-5173(92)90136-P
Pharmacokinetics of receptor-mediated hepatic uptake of glycosylated albumin in mice
M. Nishikawa (1992)
10.1016/0005-2736(95)00205-7
Effects of fusogenic and DNA-binding amphiphilic compounds on the receptor-mediated gene transfer into hepatic cells by asialofetuin-labeled liposomes.
T. Hara (1996)
10.1007/s13317-012-0041-4
Asialoglycoprotein receptor (ASGPR): a peculiar target of liver-specific autoimmunity
D. Roggenbuck (2012)
10.1016/j.exger.2005.06.009
Age-related changes in liver structure and function: Implications for disease ?
D. Schmucker (2005)
10.1016/j.jconrel.2014.05.016
Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice.
Y. Zou (2014)
10.2174/092986708785132997
Recent trends in targeted anticancer prodrug and conjugate design.
Yashveer Singh (2008)
10.1155/2012/283974
ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript Profile
Rebecca Harris (2012)
10.1096/fasebj.6.13.1397841
Biochemistry of carbohydrate‐protein interaction 1
Y. Lee (1992)
10.1111/j.2042-7158.2012.01497.x
Targeted gene delivery to hepatocytes with galactosylated amphiphilic cyclodextrins
A. Mcmahon (2012)
Hepatocyte-directed gene transfer in vivo leads to transient improvement of hypercholesterolemia in low density lipoprotein receptor-deficient rabbits.
J. Wilson (1992)
10.1155/2013/382184
Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance
Nidhi Mishra (2013)
10.1016/J.EJPS.2004.04.014
Cellular disposition of arabinogalactan in primary cultured rat hepatocytes.
T. Tanaka (2004)
10.1021/bc100525y
Galactosylated N-2-hydroxypropyl methacrylamide-b-N-3-guanidinopropyl methacrylamide block copolymers as hepatocyte-targeting gene carriers.
Z. Qin (2011)
10.1016/S0969-8051(97)00222-9
Cellular distribution of 111In-LDTPA galactose BSA in normal and asialoglycoprotein receptor-deficient mouse liver.
K. Deal (1998)
10.1007/s11604-011-0041-8
Fused 99m-Tc-GSA SPECT/CT imaging for the preoperative evaluation of postoperative liver function: can the liver uptake index predict postoperative hepatic functional reserve?
M. Yoshida (2011)
10.3109/10611861003599479
Photodynamic therapy of fullerene modified with pullulan on hepatoma cells
J. Liu (2010)
10.1021/ja807711w
In vitro imaging and in vivo liver targeting with carbohydrate capped quantum dots.
Raghavendra Kikkeri (2009)
10.1016/0169-409X(94)90005-1
Targeting of antiviral drugs to the liver using glycoprotein carriers
L. Fiume (1994)
10.1042/0264-6021:3480113
Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor's lectin properties.
D. Mcabee (2000)
10.1007/s00018-009-0053-z
Nanocarriers’ entry into the cell: relevance to drug delivery
H. Hillaireau (2009)
10.2174/156720108785915069
Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development.
Y. Li (2008)
10.1016/0014-5793(92)80669-8
Phorbol ester‐induced redistribution of the ASGP receptor is independent of receptor phosphorylation
I. Geffen (1992)
10.1016/S0168-3659(00)00338-2
Controlled biodistribution of galactosylated liposomes and incorporated probucol in hepatocyte-selective drug targeting.
Y. Hattori (2000)
10.1021/MZ400577P
Glyco-regioisomerism Effect on Lectin-Binding and Cell-Uptake Pathway of Glycopolymer-Containing Nanoparticles
P. Sun (2014)
10.1191/096032701682693017
Preclinical evaluation of the cardiotoxicity of PK2: A novel HPMA copolymer–doxorubicin–galactosamine conjugate antitumour agent
J. Hopewell (2001)
10.1248/BPB.21.741
Targeting of soybean-derived sterylglucoside liposomes to liver tumors in rat and mouse models.
K. Shimizu (1998)
10.1016/j.jconrel.2010.10.014
Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates.
T. Ishihara (2011)
10.1016/S0168-3659(96)01577-5
Targeted delivery of drugs and proteins to the liver via receptor-mediated endocytosis
M. Hashida (1997)
10.1042/BJ2700233
Uptake of lactosylated low-density lipoprotein by galactose-specific receptors in rat liver.
M. Bijsterbosch (1990)
10.1016/S0006-2952(99)00327-5
Enhanced liver blood concentrations of adenine arabinoside accomplished by lactosaminated poly-L-lysine coupling: implications for regional chemotherapy of hepatic micrometastases.
G. Di Stefano (2000)
10.1080/10611860801902351
Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetate
Jiafang Lian (2008)
10.1021/ja106206z
Hepatocyte targeting and intracellular copper chelation by a thiol-containing glycocyclopeptide.
A. Pujol (2011)
10.1023/A:1021433206081
Targeting Efficiency of Galactosylated Liposomes to Hepatocytes in Vivo: Effect of Lipid Composition
A. Murao (2004)
Development of a hepatocyte-specific prostaglandin E(1) polymeric prodrug and its potential for preventing carbon tetrachloride-induced fulminant hepatitis in mice.
K. Akamatsu (1999)
10.2217/nnm.10.27
Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation.
W. Wei (2010)
10.1016/S0168-3659(00)00368-0
Evidence for receptor-mediated hepatic uptake of pullulan in rats.
Y. Kaneo (2001)
10.1016/S0168-3659(00)00356-4
Biological characteristics of lactosaminated N-succinyl-chitosan as a liver-specific drug carrier in mice.
Y. Kato (2001)
10.1016/0014-5793(79)81247-8
Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin
L. Fiume (1979)
Turnover of the surface proteins and the receptor for serum asialoglycoproteins in primary cultures of rat hepatocytes.
R. Warren (1981)
10.1111/J.1432-1033.1982.TB19780.X
Effects of streptozotocin-induced diabetes mellitus on the binding and uptake of asialoorosomucoïd by isolated hepatocytes from rats.
M. Dodeur (1982)
10.1016/J.BIOMATERIALS.2004.09.025
Alginate microcapsules prepared with xyloglucan as a synthetic extracellular matrix for hepatocyte attachment.
Seog-Jin Seo (2005)
10.1136/gut.25.12.1392
Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate (ara-AMP) in mouse liver.
L. Fiume (1984)
10.1016/j.jconrel.2010.05.030
In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes.
Hidetoshi Arima (2010)
10.1128/JVI.77.1.546-559.2003
Role of the Asialoglycoprotein Receptor in Binding and Entry of Hepatitis C Virus Structural Proteins in Cultured Human Hepatocytes
B. Saunier (2003)
10.1016/j.nano.2009.07.006
Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Q. Wang (2010)
10.3109/08982104.2012.662653
Galactosylated nanostructured lipid carriers for delivery of 5-FU to hepatocellular carcinoma
J. Varshosaz (2012)
10.1074/jbc.274.21.14750
Copper and Zinc Ions Differentially Block Asialoglycoprotein Receptor-mediated Endocytosis in Isolated Rat Hepatocytes*
D. Mcabee (1999)
10.1007/s11051-013-2136-x
Lactosaminated-N-succinyl chitosan nanoparticles for hepatocyte-targeted delivery of acyclovir
Nivrati Jain (2013)
10.1080/00397910903161827
Synthesis of Multivalent Galactosides as Targeting Ligand for Gene Delivery
L. Hai (2010)
10.1006/BBRC.1998.9602
Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes.
S. Kawakami (1998)
10.1021/BC00030A017
Targeted delivery of DNA using YEE(GalNAcAH)3, a synthetic glycopeptide ligand for the asialoglycoprotein receptor.
J. Merwin (1994)
10.1097/01.sla.0000205826.62911.a7
The Adaptive Response of the Reticuloendothelial System to Major Liver Resection in Humans
M. J. Schindl (2006)
Targeted delivery of plasmid DNA to hepatocytes in vivo: optimization of the pharmacokinetics of plasmid DNA/galactosylated poly(L-lysine) complexes by controlling their physicochemical properties.
M. Nishikawa (1998)
10.1038/sj.bjc.6690708
The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells
D. Treré (1999)
10.1023/B:GLYC.0000045095.86867.c0
Ligands of the asialoglycoprotein receptor for targeted gene delivery, part 1: Synthesis of and binding studies with biotinylated cluster glycosides containing N-acetylgalactosamine
Ulrika Westerlind (2004)
10.1016/S0142-9612(01)00129-6
Galactosylated alginate as a scaffold for hepatocytes entrapment.
Jun Yang (2002)
10.1016/S0304-4165(99)00031-8
Liver uptake and hepato-biliary transfer of galactosylated proteins in rats are determined by the extent of galactosylation.
F. Štaud (1999)
10.1038/298398A0
Receptor-rich intracellular membrane vesicles transporting asialotransferrin and insulin in liver
M. T. Debanne (1982)
10.1016/j.canlet.2012.07.024
Capturing circulating tumor cells of hepatocellular carcinoma.
L. Wu (2012)
10.1016/S0169-409X(01)00209-5
Cell-specific delivery of genes with glycosylated carriers.
M. Hashida (2001)
10.1016/S0378-5173(03)00128-5
Development of polymeric nanoparticulate drug delivery systems: evaluation of nanoparticles based on biotinylated poly(ethylene glycol) with sugar moiety.
I. Kim (2003)
10.1007/s11095-006-9609-x
Effective Targeting of Liposomes to Liver and Hepatocytes In Vivo by Incorporation of a Plasmodium Amino Acid Sequence
K. Longmuir (2006)
10.1074/jbc.273.31.19502
Mechanism of N-Acetylgalactosamine Binding to a C-type Animal Lectin Carbohydrate-recognition Domain*
A. Kolatkar (1998)
10.1016/j.ijpharm.2009.05.045
Amphiphilic perfluoroalkyl carbohydrates as new tools for liver imaging.
C. Richard (2009)
10.1021/bc100346n
Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation.
L. Zhu (2010)
10.3109/10611869808997897
Disposition characteristics of glycosylated poly(amino acids) as liver cell-specific drug carrier.
K. Akamatsu (1998)
10.1200/JCO.20.6.1668
Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
L. Seymour (2002)
10.1016/j.biomaterials.2008.11.027
Galactosylated fluorescent labeled micelles as a liver targeting drug carrier.
De-Qun Wu (2009)
10.1016/j.ijbiomac.2008.06.006
The use of solid lipid nanoparticles to target a lipophilic molecule to the liver after intravenous administration to mice.
W. Lu (2008)
10.1016/J.MAM.2007.09.008
Hepatocellular carcinoma: epidemiology and clinical aspects.
R. Mazzanti (2008)
10.3390/ijms140815755
Galactosylated Chitosan Oligosaccharide Nanoparticles for Hepatocellular Carcinoma Cell-Targeted Delivery of Adenosine Triphosphate
Xiu Liang Zhu (2013)
10.1016/j.colsurfb.2013.04.022
Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells.
R. Villa (2013)
10.1155/2010/863136
Synthesis, and characterization, and evaluation of cellular effects of the FOL-PEG-g-PEI-GAL nanoparticles as a potential non-viral vector for gene delivery
S. Ghiamkazemi (2010)
10.1615/CRITREVTHERDRUGCARRIERSYST.V19.I2.30
Glycosylated cationic liposomes for cell-selective gene delivery.
S. Kawakami (2002)
10.1002/JBM.A.10033
High density of immobilized galactose ligand enhances hepatocyte attachment and function.
C. Yin (2003)
10.1093/GLYCOB/6.5.551
Differential ligand binding by two subunits of the rat liver asialoglycoprotein receptor.
N. I. Ruíz (1996)
10.1016/0006-2952(93)90273-Y
Hepatic and intrahepatic targeting of an anti-inflammatory agent with human serum albumin and neoglycoproteins as carrier molecules.
E. Franssen (1993)
10.1021/BC050113D
A nanoparticle-based model delivery system to guide the rational design of gene delivery to the liver. 1. Synthesis and characterization.
S. R. Popielarski (2005)
10.1016/J.JCONREL.2005.03.024
Synergistic effect of poly(ethylenimine) on the transfection efficiency of galactosylated chitosan/DNA complexes.
T. Kim (2005)
10.1016/J.BIOMATERIALS.2005.09.018
Enhanced liver functions of hepatocytes cocultured with NIH 3T3 in the alginate/galactosylated chitosan scaffold.
Seog-Jin Seo (2006)
10.1016/J.NUCMEDBIO.2006.03.005
Asialoglycoprotein-receptor-targeted hepatocyte imaging using 99mTc galactosylated chitosan.
E. Kim (2006)
10.1016/J.BIOMATERIALS.2003.10.004
Novel receptor-mediated gene delivery system comprising plasmid/protamine/sugar-containing polyanion ternary complex.
K. Maruyama (2004)
10.1074/JBC.M101786200
Determination of the Upper Size Limit for Uptake and Processing of Ligands by the Asialoglycoprotein Receptor on Hepatocytesin Vitro and in Vivo *
P. C. Rensen (2001)
10.1002/marc.201300538
Galactose-functionalized cationic polycarbonate diblock copolymer for targeted gene delivery to hepatocytes.
Z. Y. Ong (2013)
10.1016/j.mri.2010.02.003
Molecular imaging contrast media for visualization of liver function.
Matsuoka Yoshinori (2010)



This paper is referenced by
10.3390/ncrna6010012
Long Non-coding RNAs Mechanisms of Action in HIV-1 Modulation and the Identification of Novel Therapeutic Targets
R. Ray (2020)
10.1016/j.biopha.2019.109128
Traditional Chinese medicine combined with hepatic targeted drug delivery systems: A new strategy for the treatment of liver diseases.
Zhe Ma (2019)
Homing in on the hepatic scar : recent advances in cell-specific targeting of liver fibrosis
F. Tacke (2018)
10.1016/j.addr.2019.06.008
Absorption, distribution, metabolism and excretion of the biomaterials used in Nanocarrier drug delivery systems.
Chong Su (2019)
10.1016/j.omtn.2020.01.034
Aptamer-Functionalized Drug Nanocarrier Improves Hepatocellular Carcinoma toward Normal by Targeting Neoplastic Hepatocytes
Samrat Chakraborty (2020)
10.1177/0885328220903950
Galactose-functionalized GlycoAuNR as a photothermal conversion complex: Its binding to lectin RCA120 and hepatoma-targeting therapy
Y. Zheng (2020)
10.1007/978-981-15-0391-7
Nanoparticles and their Biomedical Applications
Ajit Kumar N. Shukla (2020)
Nouveaux peptides chélateurs du Cu(I) comme candidat potentiel pour le traitement de maladie de Wilson
Edit Mesterházy (2018)
10.1038/s41598-019-52142-4
Therapeutic potential of functionalized siRNA nanoparticles on regression of liver cancer in experimental mice
A. Khan (2019)
10.1016/j.carbpol.2015.10.021
Bioenhanced oral curcumin nanoparticles: Role of carbohydrates.
A. D’souza (2016)
Nanosized systems for efficient delivery of antitumoral and anti-inflammatory drugs
R. Pireddu (2015)
10.1021/acs.chemrev.5b00589
Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies.
K. Ulbrich (2016)
10.1371/journal.pone.0219752
Design of bile-based vesicles (BBVs) for hepatocytes specific delivery of Daclatasvir: Comparison of ex-vivo transenterocytic transport, in-vitro protein adsorption resistance and HepG2 cellular uptake of charged and β-sitosterol decorated vesicles
Amira A Boseila (2019)
10.1126/sciadv.aba2983
CRISPR-Cas12a delivery by DNA-mediated bioresponsive editing for cholesterol regulation
W. Sun (2020)
10.1007/978-3-030-30930-5_11
Nanocarrier-Mediated Drug Delivery Systems for Neurodegenerative Diseases
Sathika G. G. Arachchige (2019)
10.1039/C8RA01424H
A galactose-mediated targeting nanoprobe for intracellular hydroxyl radical imaging to predict drug-induced liver injury
Bailing Ma (2018)
10.1016/j.colsurfb.2017.01.017
Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma.
Lê Quang Thảo (2017)
10.1002/chem.202003084
Photoregulation of Gene Expression with Amantadine-modified Caged siRNAs Through Host/Guest Interaction.
Jinhao Zhang (2020)
10.1016/J.JIEC.2019.03.016
Phenylboronic acid-conjugated cationic methylcellulose for hepatocellular carcinoma-targeted drug/gene co-delivery systems
Ju Hyeon Jeon (2019)
10.1080/21691401.2017.1421210
Pharmacokinetics, biodistribution and receptor mediated endocytosis of a natural Angelica sinensis polysaccharide
Y. Zhang (2018)
10.1039/d0tb00285b
Redox-responsive amphiphilic camptothecin prodrug nanoparticles for targeted liver tumor therapy.
Lu Lu (2020)
10.1016/j.ejps.2019.104978
Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Lakshmi Tunki (2019)
10.1093/nar/gkx1239
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs
Xiulong Shen (2018)
10.1039/c7cc02363d
Conjugated polyelectrolytes with galactose-containing side chains for targeted hepatoma cell imaging.
Mingli Zhang (2017)
10.1002/adfm.201910084
Fabrication of Glyco‐Metal‐Organic Frameworks for Targeted Interventional Photodynamic/Chemotherapy for Hepatocellular Carcinoma through Percutaneous Transperitoneal Puncture
J. Hu (2020)
10.1016/j.ijpharm.2017.03.065
Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin.
H. Du (2017)
10.1016/j.carbpol.2016.11.094
Efficient delivery of paclitaxel into ASGPR over-expressed cancer cells using reversibly stabilized multifunctional pullulan nanoparticles.
L. Huang (2017)
10.1016/bs.pmbts.2018.12.012
Serum CA125 levels are decreased in rectal cancer but increased in fibrosis-associated diseases and in most types of cancers.
M. Zhang (2019)
10.4155/bio-2019-0194
Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
Daniel A Norris (2019)
10.25177/JNMS.2.1.RA.410
In vitro cytotoxicity studies on galactosylated chitosan nanoparticles for the delivery of oridonin to liver
Jinglong Wang (2019)
10.1093/nar/gkx060
Characterizing the effect of GalNAc and phosphorothioate backbone on binding of antisense oligonucleotides to the asialoglycoprotein receptor
K. Schmidt (2017)
10.1016/j.ejpb.2019.05.015
Targeted delivery and endosomal cellular uptake of DARPin-siRNA bioconjugates: Influence of linker stability on gene silencing.
Cornelia Lorenzer (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar